Nuvalent Liabilities And Stockholders Equity from 2010 to 2024

NUVL Stock  USD 86.86  0.04  0.05%   
Nuvalent Liabilities And Stockholders Equity yearly trend continues to be quite stable with very little volatility. Liabilities And Stockholders Equity may rise above about 769 M this year. Liabilities And Stockholders Equity is the total of all liabilities and equity in the company, which should equal Nuvalent's total assets according to the accounting equation. View All Fundamentals
 
Liabilities And Stockholders Equity  
First Reported
2010-12-31
Previous Quarter
732.4 M
Current Value
769 M
Quarterly Volatility
278.7 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Nuvalent financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Nuvalent's main balance sheet or income statement drivers, such as Depreciation And Amortization of 159.5 K, Interest Expense of 24.4 M or Selling General Administrative of 38.1 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 6.42. Nuvalent financial statements analysis is a perfect complement when working with Nuvalent Valuation or Volatility modules.
  
Check out the analysis of Nuvalent Correlation against competitors.
For more information on how to buy Nuvalent Stock please use our How to buy in Nuvalent Stock guide.

Latest Nuvalent's Liabilities And Stockholders Equity Growth Pattern

Below is the plot of the Liabilities And Stockholders Equity of Nuvalent over the last few years. It is the total of all liabilities and equity in the company, which should equal the company's total assets according to the accounting equation. Nuvalent's Liabilities And Stockholders Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Nuvalent's overall financial position and show how it may be relating to other accounts over time.
Liabilities And Stockholders Equity10 Years Trend
Slightly volatile
   Liabilities And Stockholders Equity   
       Timeline  

Nuvalent Liabilities And Stockholders Equity Regression Statistics

Arithmetic Mean154,765,080
Geometric Mean13,879,370
Coefficient Of Variation180.11
Mean Deviation221,147,984
Median3,316,000
Standard Deviation278,746,085
Sample Variance77699.4T
Range765.7M
R-Value0.76
Mean Square Error34978.1T
R-Squared0.58
Significance0.0009
Slope47,549,841
Total Sum of Squares1087791.3T

Nuvalent Liabilities And Stockholders Equity History

2024769 M
2023732.4 M
2022482.5 M
2021293.8 M
202010.6 M

About Nuvalent Financial Statements

Nuvalent investors utilize fundamental indicators, such as Liabilities And Stockholders Equity, to predict how Nuvalent Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Liabilities And Stockholders Equity732.4 M769 M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Nuvalent is a strong investment it is important to analyze Nuvalent's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Nuvalent's future performance. For an informed investment choice regarding Nuvalent Stock, refer to the following important reports:
Check out the analysis of Nuvalent Correlation against competitors.
For more information on how to buy Nuvalent Stock please use our How to buy in Nuvalent Stock guide.
You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Nuvalent. If investors know Nuvalent will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Nuvalent listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(3.49)
Return On Assets
(0.19)
Return On Equity
(0.30)
The market value of Nuvalent is measured differently than its book value, which is the value of Nuvalent that is recorded on the company's balance sheet. Investors also form their own opinion of Nuvalent's value that differs from its market value or its book value, called intrinsic value, which is Nuvalent's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Nuvalent's market value can be influenced by many factors that don't directly affect Nuvalent's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Nuvalent's value and its price as these two are different measures arrived at by different means. Investors typically determine if Nuvalent is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Nuvalent's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.